Latest International Expansion News

Rhythm Biosciences has begun commercialising its blood-based colorectal cancer test, ColoSTAT®, following key accreditations and validation. The company also secured a strategic partnership with NHS England and expanded its geneType™ platform globally.

Osteopore Limited has secured an exclusive agreement with MontsMed Hong Kong to introduce its innovative 3D-printed orthopaedic implants into Hong Kong, positioning itself strategically within the Greater Bay Area’s burgeoning medical market.

Chilwa Minerals has finalised the last tranche of its $8 million private placement, bolstered by insider participation, and is advancing plans for a Nasdaq dual listing in the first half of 2026.

Genetic Signatures reported a $3.3 million quarterly revenue with growing international sales and a robust cash position, while preparing for a leadership change.

Advanced Braking Technology Ltd reports a robust Q2 FY26 with a 34% increase in product sales revenue and a 191% jump in net profit before tax, underpinned by strong international expansion and domestic contract wins.

Alcidion Group has been named preferred supplier for a major UK hospital's Electronic Patient Record system, driving a 40% jump in contracted revenue and a robust cash position in Q2 FY26.

Neuren Pharmaceuticals’ partner Acadia projects DAYBUE sales to reach around US$700 million by 2028, driven by US market expansion and international approvals. The launch of a new formulation and ongoing clinical trials in Japan underpin this optimistic outlook.

ECS Botanics reports a $218k positive operating cash flow in Q2 FY26, driven by strong B2C growth and new product launches. The company also secured $1.95 million in funding to fuel European expansion and product development.

RocketBoots Limited has slightly increased its recent capital raising, issuing an additional 100,000 shares to raise a total of A$7.025 million, reinforcing its push into international markets.

Janus Electric has appointed Ben Hutt as CEO and Managing Director, aiming to fast-track its innovative exchangeable battery systems for heavy transport. Hutt’s extensive energy transition and capital markets experience positions the company for its next growth phase.

ReNerve Limited has secured broader regulatory approval in Hong Kong for its NervAlign® Nerve Cuff, enabling access to both public and private hospitals and validating the device’s clinical benefits through independent review.

CurveBeam AI has received official Chinese regulatory approval for a strategic $10 million investment from WEGO Orthopaedics, marking a major step in its expansion into Greater China. The initial $4 million tranche at a premium share price is expected imminently, underpinning a decade-long commercialisation deal.